May Also by Useful in Treating Osteoporosis by startup OrthoStim 

July 2nd, 2020

IRVINE, CALIFORNIA –(PR Distribution)- CancerCell, a biotechnology LTP stage startup within the Leonhardt’s Launchpads innovation and startup launch accelerator(s), announced the filing of a U.S. patent application relating to its novel bioelectric signaling technology targeting specific cancers such as multiple myeloma.  The technology is based on bioelectric controlled expression of OPG to inhibit RANKL over production which eats away at bone in multiple myeloma patients and contributes to the spread of other cancers such as lung cancers. These filed patent claims are broad and add to CancerCell’s growing IP estate with 9 U.S. issued patents already for bioelectric cancer treatment and dozens of additional claims from separate filings pending

The multi-modality bioelectric cancer treatment protocol being developed by CancerCell is composed of certain novel bioelectric signaling sequences for controlling specific actions.  The treatment is customized based on reading the cancer tumors real time with specific signaling sequences delivered customized based on that read.  The first wave of bioelectric signals sent to the tumors are designed to jam their communication. The 2nd set of signals are designed to change the surface proteins and electrical surface charge of the tumors to elicit an immune response from the body to kill off the tumor. These signals are specifically designed to elicit a T cell response targeting the proliferating cancer cells. The 3rd wave of treatment is designed to starve a tumor of blood supply by controlled release of anti-angiogenic proteins. The 4th wave of signaling targets the re-programming of cancer cells to re-direct their tumor development pathway. After all of these treatment phases are completed the bioelectric signaling sequences transition to a promotion of healing and regeneration of the diseased organ including bioelectric inflammation management.

“My Mother Penelope Leonhardt passed away from multiple myeloma cancer at age 49 so this particular new patent filing and development is particularly important to me personally.” states Howard J. Leonhardt, Inventor, Executive Chairman & CEO  “A number of published studies have linked  a role of RANK/RANKL in patients with multiple myeloma, who have increased serum levels of soluble RANKL and an imbalance in RANKL and OPG osteoprotegerin. Recent multiple myeloma research demonstrate that RANKL may be released by tumor cells or OPG osteoprogenitor cells. This RANKL over expression in simple terms eats away and destroys bone in these patients. This patent filing and the upcoming related studies focus on applying bioelectric controlled release of OPG at the precise right customized levels to inhibit over expression of RANKL, create a RANKL/OPG balance, and thus hopefully halt rapid bone degradation in multiple myeloma patients. We plan to utilize our other bioelectric signal treatment protocols previously patented or patent pending to attempt to get the cancer spread under control and eventually the patient restored back to full health.” Leonhardt further stated.

The CancerCell team completed a previous pre-clincial short duration treatment feasibility study at UCLA last year and has moved on to launching a 2nd round of pre-clincial studies in Brazil this summer for attempting to halt cancer tumor growth.  Howard Leonhardt traveled to Brazil last year and met with over a dozen cancer researchers in Porto Allegre, Brazil. This study will be supervised in Brazil by Dr. Cristiane Carboni whom is Research Coordinator at Leonhardt’s Launchpads Brazil working in collaboration with leading cancer researchers in the area (separate announcement to be released soon).

About Bioelectric OPG Control for Multiple Myeloma

Previous research focused on injecting or infusing OPG or the utilization of drugs for inhibiting RANKL over expression and thus reducing or stopping bone degradation. This new patent describes for the first time bioelectric signaling means for controlled OPG expression to inhibit RANKL over expression and thus bone degradation.

Bone Lesions in Multiple Myeloma–The OPG/RANK-ligand System. Reference Link:

Abstract – Multiple myeloma has recently been found to induce considerable imbalance in the newly identified system of osteoprotegerin (OPG), receptor activator of nuclear factor KB ligand (RANKL) and RANK. The binding of RANKL to RANK on the surface of osteoclastic precursors in the presence of m-CSF activates the signalling pathways for differentiation and proliferation of an osteoclastic line. OPG is a decoy circulating receptor for RANKL which blocks its binding to RANK. There are at least three mechanisms by which myeloma cells affects the OPG/ RANKL/RANK system: 1: The adhesion between the myeloma / stromal cells and the osteoblastic precursors stimulates the system by increasing the production of RANKL. 2: Some myeloma lines produce independently membrane-bound or free RANKL. 3: The normal and mutated plasma cells bind, degrade and block the OPG production from the stromal cells. The OPG/RANKL/RANK system is the latest therapeutic target in the treatment of myeloma bone disease. The first results from the application of a synthetic analogue of OPG, as well as of RANKL antagonists or RANK inhibitors show decrease of the number of osteoclasts, osteolytic lesions and M-gradient.

Many studies have also linked the benefits or potential benefits of RANKL inhibition via OPG for treating osteoporosis.

Role of RANKL inhibition in osteoporosis

OrthoStim http://www.ortho-stim.comanother Licensable Technology Platform startup within the Leonhardt’s Launchpad’s innovation and startup launch accelerator will pursue developing an bioelectric OPG treatment solution for osteoporosis.

Both the cancer and osteoporosis treatment study protocols will eventually have an arm treated with not only bioelectric stimulation but also a combination of bioelectrics and repeat biologics or drugs delivered via Leonhardt’s patented combination stimulator and re-fillable micro infusion pump

About CancerCell and Leonhardt’s Launchpads 

CancerCell is an Irvine, California based pre-clinical-stage startup within the Leonhardt’s Launchpads innovation and startup launch accelerator(s) that is developing bioelectric and biologics based therapies for the treatment of cancers.  CancerCell’s lead product candidate—is a multi-modality bioelectric cancer treatment protocol based on reading cancer tumors and custom delivering communication jamming signals, surface protein and charge change signals to elicit and an immune response, starving a tumor of blood supply and reprogramming cancer tumor cells following by healing, inflammation and organ regeneration signaling sequences.  In particularly difficult cases the bioelectric therapy will be combined with other therapeutics such as biologics, chemo or radiation.  Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc. based in Irvine, California is the innovation and startup launch accelerator arm of Leonhardt Ventures LLC (Leonhardt Vineyards LLC DBA Leonhardt Ventures) with branches and subsidiaries in Utah, Pittsburgh, Minneapolis, Australia and Brazil.  The Leonhardt team has been developing breakthrough medtech and biotech innovations since the 1980’s.  See the full Leonhardt’s Launchpads 2020 portfolio of innovations, Licensable Technology Platforms and startups.

Link to Leonhardt’s Launchpads Annual Report > content/uploads/2020/04/4_23_2020.pdf

About OrthoStim

OrthoStim http://www.ortho-stim.comis a Licensable Technology Platform (LTP) stage startup within the Leonhardt’s Launchpads accelerator(s) focused on applying bioelectrics and biologics to treating orthopedic disorders including muscle, tendons, bone and joints.  OrthoStim has created OrthoStim Acceleator to pursue venture creation launching sub-startups for specific applications of use of our core IP.

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including without limitation the risks associated with generating data to support the patent application for the CancerCell technology and of obtaining a patent that provides commercially significant protection for this technology; the risk that the CancerCell technology may infringe the proprietary rights of third parties; the risks associated with obtaining FDA clearance to commence clinical trials of the cancer stem vaccine on a timely basis or at all; the need to satisfy performance milestones to maintain the licenses with third parties such as Codes for Life and Neuro Code Tech Holdings LLC ; the risks associated with adhering to projected preclinical or clinical timelines and the uncertainties of outcomes of development work for product candidates, including those based on eradicating cancer as a potentially effective treatment to the slow the growth of various cancers; and the need for substantial additional capital to fund development of product candidates beyond their initial clinical or pre-clinical stages. Additional risks and uncertainties are described in Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc. most recently published Annual Report, Investor FAQs page and Private Placement Memorandum documents.  CancerCell and Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc. and all of its related branches and subsidiaries and development partners undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  The above is all the same for the mention of OrthoStim’s pursuit of developed an OPG treatment option for osteoporosis.


Brian Hardy
Director of Marketing
Phone : (424) 291-2133

Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc.,

18575 Jamboree Rd #6, Irvine, CA 92612

Leonhardt’s Launchpads Utah, Inc. 
Research Lab @ 2500 S State St. #D249, Salt Lake City, UT 84115